Stellaromics
Boston, United States · Biotechnology · 52 employees
Stellaromics is a biotechnology company that specializes in 3D in situ multi-omic analysis technology.
Funding history
- Series series b — $80.0M — Feb 2025
- Funding Round — $25.0M — Nov 2023
Recent signals
- May 13, 2026: Stellaromics Appoints Veronica Mankinen as Senior VP and John Leamon as Senior VP
- Feb 11, 2025: Raised $80.0M in Series series b
- Feb 11, 2025: Launched Stellaromics Launches Pyxa, a Revolutionary Platform for 3D Spatial Biology Research Following $80M Funding.
- Nov 02, 2023: Raised $25.0M
See plans & pricing → Track Stellaromics’s funding, hiring, and signals — with verified contacts — on Fundz.